Matches in UGent Biblio for { <https://biblio.ugent.be/publication/1142429#aggregation> ?p ?o. }
Showing items 1 to 51 of
51
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B334950.
- aggregation creator B334951.
- aggregation creator B334952.
- aggregation creator B334953.
- aggregation creator B334954.
- aggregation creator B334955.
- aggregation creator B334956.
- aggregation creator B334957.
- aggregation creator B334958.
- aggregation creator B334959.
- aggregation creator B334960.
- aggregation creator B334961.
- aggregation creator B334962.
- aggregation creator B334963.
- aggregation creator B334964.
- aggregation creator B334965.
- aggregation creator B334966.
- aggregation creator B334967.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2010".
- aggregation format "application/pdf".
- aggregation hasFormat 1142429.bibtex.
- aggregation hasFormat 1142429.csv.
- aggregation hasFormat 1142429.dc.
- aggregation hasFormat 1142429.didl.
- aggregation hasFormat 1142429.doc.
- aggregation hasFormat 1142429.json.
- aggregation hasFormat 1142429.mets.
- aggregation hasFormat 1142429.mods.
- aggregation hasFormat 1142429.rdf.
- aggregation hasFormat 1142429.ris.
- aggregation hasFormat 1142429.txt.
- aggregation hasFormat 1142429.xls.
- aggregation hasFormat 1142429.yaml.
- aggregation isPartOf urn:issn:0006-4971.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951".
- aggregation abstract "The European Organisation for Research and Treatment of Cancer 58951 trial for children with acute lymphoblastic leukemia (ALL) or non-Hodgkin lymphoma (NHL) addressed 3 randomized questions, including the evaluation of dexamethasone (DEX) versus prednisolone (PRED) in induction and, for average-risk patients, the evaluation of vincristine and corticosteroid pulses during continuation therapy. The corticosteroid used in the pulses was that assigned at induction. Overall, 411 patients were randomly assigned: 202 initially randomly assigned to PRED (60 mg/m(2)/d), 201 to DEX (6 mg/m(2)/d), and 8 nonrandomly assigned to PRED. At a median follow-up of 6.3 years, there were 19 versus 34 events for pulses versus no pulses; 6-year disease-free survival (DFS) rate was 90.6% (standard error [SE], 2.1%) and 82.8% (SE, 2.8%), respectively (hazard ratio [HR] = 0.54; 95% confidence interval, 0.31-0.94; P = .027). The effect of pulses was similar in the PRED (HR = 0.56) and DEX groups (HR = 0.59) but more pronounced in girls (HR = 0.24) than in boys (HR = 0.71). Grade 3 to 4 hepatic toxicity was 30% versus 40% in pulses versus no pulses group and grade 2 to 3 osteonecrosis was 4.4% versus 2%. For average-risk patients treated according to Berlin-Frankfurt-Muenster-based protocols, pulses should become a standard component of therapy. This trial was registered at www.clinicaltrials.gov as #NCT00003728.".
- aggregation authorList BK630824.
- aggregation endPage "44".
- aggregation issue "1".
- aggregation startPage "36".
- aggregation volume "116".
- aggregation aggregates 1150368.
- aggregation isDescribedBy 1142429.
- aggregation similarTo blood-2009-10-247965.
- aggregation similarTo LU-1142429.